173 related articles for article (PubMed ID: 25706397)
1. Inhibition of canonical NF-κB nuclear localization by (-)-DHMEQ via impairment of DNA binding.
Horie K; Ma J; Umezawa K
Oncol Res; 2015; 22(2):105-15. PubMed ID: 25706397
[TBL] [Abstract][Full Text] [Related]
2. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
[TBL] [Abstract][Full Text] [Related]
3. Involvement of DNA binding domain in the cellular stability and importin affinity of NF-κB component RelB.
Takeiri M; Horie K; Takahashi D; Watanabe M; Horie R; Simizu S; Umezawa K
Org Biomol Chem; 2012 Apr; 10(15):3053-9. PubMed ID: 22395283
[TBL] [Abstract][Full Text] [Related]
4. Anoikis induction and inhibition of peritoneal metastasis of pancreatic cancer cells by a nuclear factor-κB inhibitor, (-)-DHMEQ.
Sato M; Nakanishi K; Haga S; Fujiyoshi M; Baba M; Mino K; ; Niwa H; Yokoo H; Umezawa K; Ohmiya Y; Kamiyama T; Todo S; Taketomi A; Ozaki M
Oncol Res; 2013; 21(6):333-43. PubMed ID: 25198663
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin.
Ariga A; Namekawa J; Matsumoto N; Inoue J; Umezawa K
J Biol Chem; 2002 Jul; 277(27):24625-30. PubMed ID: 11983688
[TBL] [Abstract][Full Text] [Related]
6. Molecular design and biological activities of NF-kappaB inhibitors.
Umezawa K; Chaicharoenpong C
Mol Cells; 2002 Oct; 14(2):163-7. PubMed ID: 12442886
[TBL] [Abstract][Full Text] [Related]
7. Induction of histidine decarboxylase in macrophages inhibited by the novel NF-kappaB inhibitor (-)-DHMEQ.
Suzuki E; Ninomiya Y; Umezawa K
Biochem Biophys Res Commun; 2009 Feb; 379(2):379-83. PubMed ID: 19103154
[TBL] [Abstract][Full Text] [Related]
8. A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.
Watanabe M; Dewan MZ; Okamura T; Sasaki M; Itoh K; Higashihara M; Mizoguchi H; Honda M; Sata T; Watanabe T; Yamamoto N; Umezawa K; Horie R
Int J Cancer; 2005 Mar; 114(1):32-8. PubMed ID: 15523684
[TBL] [Abstract][Full Text] [Related]
9. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
Nishimura D; Ishikawa H; Matsumoto K; Shibata H; Motoyoshi Y; Fukuta M; Kawashimo H; Goto T; Taura N; Ichikawa T; Hamasaki K; Nakao K; Umezawa K; Eguchi K
Int J Oncol; 2006 Sep; 29(3):713-9. PubMed ID: 16865289
[TBL] [Abstract][Full Text] [Related]
10. Pleiotropic potential of dehydroxymethylepoxyquinomicin for NF-κB suppression via reactive oxygen species and unfolded protein response.
Nakajima S; Kato H; Gu L; Takahashi S; Johno H; Umezawa K; Kitamura M
J Immunol; 2013 Jun; 190(12):6559-69. PubMed ID: 23690471
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
Lampiasi N; Azzolina A; D'Alessandro N; Umezawa K; McCubrey JA; Montalto G; Cervello M
Mol Pharmacol; 2009 Aug; 76(2):290-300. PubMed ID: 19461054
[TBL] [Abstract][Full Text] [Related]
12. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia.
Watanabe M; Ohsugi T; Shoda M; Ishida T; Aizawa S; Maruyama-Nagai M; Utsunomiya A; Koga S; Yamada Y; Kamihira S; Okayama A; Kikuchi H; Uozumi K; Yamaguchi K; Higashihara M; Umezawa K; Watanabe T; Horie R
Blood; 2005 Oct; 106(7):2462-71. PubMed ID: 15956280
[TBL] [Abstract][Full Text] [Related]
13. DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts.
Makino S; Mitsutake N; Nakashima M; Saenko VA; Ohtsuru A; Umezawa K; Tanaka K; Hirano A; Yamashita S
J Dermatol Sci; 2008 Sep; 51(3):171-80. PubMed ID: 18406579
[TBL] [Abstract][Full Text] [Related]
14. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, reduces chemokines and adhesion molecule expression induced by IL-1β in human corneal fibroblasts.
Inokawa S; Watanabe T; Keino H; Sato Y; Hirakata A; Okada AA; Fukuda K; Fukushima A; Umezawa K
Graefes Arch Clin Exp Ophthalmol; 2015 Apr; 253(4):557-63. PubMed ID: 25519802
[TBL] [Abstract][Full Text] [Related]
15. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Starenki DV; Namba H; Saenko VA; Ohtsuru A; Maeda S; Umezawa K; Yamashita S
Clin Cancer Res; 2004 Oct; 10(20):6821-9. PubMed ID: 15501958
[TBL] [Abstract][Full Text] [Related]
16. Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation.
Dabaghmanesh N; Matsubara A; Miyake A; Nakano K; Ishida T; Katano H; Horie R; Umezawa K; Watanabe T
Cancer Sci; 2009 Apr; 100(4):737-46. PubMed ID: 19469019
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo antitumor activity of the NF-kappaB inhibitor DHMEQ in the human T-cell leukemia virus type I-infected cell line, HUT-102.
Ohsugi T; Kumasaka T; Ishida A; Ishida T; Horie R; Watanabe T; Umezawa K; Yamaguchi K
Leuk Res; 2006 Jan; 30(1):90-7. PubMed ID: 16002138
[TBL] [Abstract][Full Text] [Related]
18. Identification of the RelA domain responsible for action of a new NF-kappaB inhibitor DHMEQ.
Watanabe M; Nakashima M; Togano T; Higashihara M; Watanabe T; Umezawa K; Horie R
Biochem Biophys Res Commun; 2008 Nov; 376(2):310-4. PubMed ID: 18782563
[TBL] [Abstract][Full Text] [Related]
19. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner.
Tatetsu H; Okuno Y; Nakamura M; Matsuno F; Sonoki T; Taniguchi I; Uneda S; Umezawa K; Mitsuya H; Hata H
Mol Cancer Ther; 2005 Jul; 4(7):1114-20. PubMed ID: 16020669
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Suzuki E; Umezawa K
Biomed Pharmacother; 2006 Nov; 60(9):578-86. PubMed ID: 16978829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]